 |
|
New Study Examines Brain-Gut Relationship in those Suffering with Stomach Pain or Discomfort (Functional Dyspepsia)
September 06, 2007A new clinical study will explore the brain-gut interaction in patients with functional dyspepsia and whether certain drugs can effectively relieve symptoms of this disorder. Functional dyspepsia is a costly and chronic disorder that can cause severe stomach pain often reported as cramping, bloating, and gas, or great discomfort or fullness after eating. The study is funded by the National Institutes of Health (NIH) at six medical centers in the U.S.
The Functional Dyspepsia Treatment Trial (FDTT) will determine if either of two FDA-approved drugs that act on both the brain and the gut are better than placebo in relieving stomach pain, or discomfort after meals, in patients with functional dyspepsia. The study will also determine whether certain genes can predict who will best respond or not respond to the medicines. Finally, the trial will determine whether participants have a continued response for six months after the medicines are stopped.
Functional dyspepsia is a commonly diagnosed disorder. The symptoms are thought to be the result of abnormal muscle activity within the stomach, which may be caused by abnormal sensitivity of the nerves in the stomach or irregular signals from the brain to the muscles in the gut. "While we do not know the exact cause of functional dyspepsia, we do know that the disorder can cause chronic and sometimes debilitating symptoms that can have a dramatic effect on the quality of life for functional dyspepsia suffers," said Patricia Robuck, Ph.D., M.P.H., project scientist for FDTT and director of the Clinical Trials Program of the Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the sponsor of the FDTT at NIH. "We are interested in learning more about the brain-gut interaction and physiological effects of these two similar but different classes of drugs on the symptoms associated with functional dyspepsia."
Currently, the treatment of functional dyspepsia is considered limited. Standard treatment includes food restriction and antisecretory drugs (H2 blockers, proton pump inhibitors) and prokinetics, which help make the stomach empty faster. Patients with dyspepsia sometimes also try alternative medicines and non-drug measures such as hypnotherapy. The effectiveness of these alternative measures remains unproven.
Results from small studies using medications like amitriptyline and escitalopram for adults with functional dyspepsia suggest that the abdominal pain and motility may get better. "We are excited by these early findings," says Nicholas J. Talley, M.D., Ph.D., chair of the trial and Chair of the Department of Internal Medicine at the Mayo Clinic, Jacksonville, Florida. "If it turns out that these drugs correct stomach emptying, stomach retention, and overall motility, we could help improve the quality of health and life for the millions of people with functional dyspepsia."
Over the next five years, researchers will enroll 400 men and women, ages 18-75 years old with functional dyspepsia who have failed to respond to antisecretory treatments for the disorder. The participants will receive amitriptyline, or escitalopram, or placebo. Patients with peptic ulcer disease, a history of drug or alcohol abuse, and past abdominal surgeries will be excluded from the trial. Women who are pregnant and patients whose reading skills are insufficient to complete self report questionnaires will also be excluded. Recruitment for the trial began in January, 2007.
The following principal investigators and clinical centers are conducting the study:
* Dr. Nicholas J. Talley, Mayo Clinic, Jacksonville, Florida (Study Chair)
* Dr. John K. Dibaise, Mayo Clinic, Scottsdale, Arizona
* Dr. Earnest P. Bouras, Mayo Clinic, Jacksonville, Florida
* Dr. G. Richard Locke, Mayo Clinic, Rochester, Minnesota
* Dr. Michael P. Jones, Northwestern University, Chicago, Illinois
* Dr. Charlene M. Prather, Saint Louis University School of Medicine, Saint Louis, Missouri
* Dr. Brian E. Lacy, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire
The National Institutes of Health (NIH)
Currently, the treatment of functional dyspepsia is considered limited. Standard treatment includes food restriction and antisecretory drugs (H2 blockers, proton pump inhibitors) and prokinetics, which help make the stomach empty faster. Patients with dyspepsia sometimes also try alternative medicines and non-drug measures such as hypnotherapy. The effectiveness of these alternative measures remains unproven.
Results from small studies using medications like amitriptyline and escitalopram for adults with functional dyspepsia suggest that the abdominal pain and motility may get better. "We are excited by these early findings," says Nicholas J. Talley, M.D., Ph.D., chair of the trial and Chair of the Department of Internal Medicine at the Mayo Clinic, Jacksonville, Florida. "If it turns out that these drugs correct stomach emptying, stomach retention, and overall motility, we could help improve the quality of health and life for the millions of people with functional dyspepsia."
Over the next five years, researchers will enroll 400 men and women, ages 18-75 years old with functional dyspepsia who have failed to respond to antisecretory treatments for the disorder. The participants will receive amitriptyline, or escitalopram, or placebo. Patients with peptic ulcer disease, a history of drug or alcohol abuse, and past abdominal surgeries will be excluded from the trial. Women who are pregnant and patients whose reading skills are insufficient to complete self report questionnaires will also be excluded. Recruitment for the trial began in January, 2007.
The following principal investigators and clinical centers are conducting the study:
* Dr. Nicholas J. Talley, Mayo Clinic, Jacksonville, Florida (Study Chair)
* Dr. John K. Dibaise, Mayo Clinic, Scottsdale, Arizona
* Dr. Earnest P. Bouras, Mayo Clinic, Jacksonville, Florida
* Dr. G. Richard Locke, Mayo Clinic, Rochester, Minnesota
* Dr. Michael P. Jones, Northwestern University, Chicago, Illinois
* Dr. Charlene M. Prather, Saint Louis University School of Medicine, Saint Louis, Missouri
* Dr. Brian E. Lacy, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire
The National Institutes of Health (NIH)
Dyspepsia Current Events and Dyspepsia News RSSAcute gastric injury due to high-dose analgesics?
Analgesics, NSAIDs and acetaminophen, are commonly used for the relief of fever, headaches, and other minor aches and pains. The gastrointestinal side effects of NSAIDs are well documented and acetaminophen is accepted to be a safe drug for the gastrointestinal system. Acute effects of short-term, especially high-dose NSAID and acetaminophen use have not been studied adequately.
Nearly 40 percent of GERD patients taking PPIs experience recurring symptoms
Despite daily use of doctor-recommended proton pump inhibitors (PPIs) to control gastroesophageal reflux disease (GERD) symptoms, nearly 40 percent of patients who take them continue to experience breakthrough, which is a return of GERD symptoms, such as acid regurgitation and heartburn.
A strange case of upper obstructive syndrome
Aorto-duodenal fistulae (ADF) are the most frequent aorto-enteric fistulae (80%) and the most frequent presenting sign of ADF is upper gastrointestinal bleeding (UGI).
ASGE offers guidelines on endoscopic treatment of dyspepsia
The American Society for Gastrointestinal Endoscopy (ASGE) has issued guidelines for the role of endoscopy in treating dyspepsia, discomfort thought to arise from the upper-gastrointestinal tract, which affects a fourth of the population in Western countries.
Study measures impact on productivity from functional gastrointestinal disorders
Those who suffer from common functional gastrointestinal disorders face work productivity losses and impairments in daily activity that amount to the loss of at least one day of work in a 40-hour workweek.
Common abdominal pain may be due to a potentially treatable newly recognized inflammatory reaction
As many as one in four people in westernized countries experience pain or discomfort in their upper abdomen, and physicians have almost nothing to offer except anti-acid medicines, which usually don't work.
To avoid stomach upset in arthritis patients, drug combination more effective
UCLA/VA researchers found that for arthritis patients, taking a combination of two drugs may be most effective in protecting against stomach upset called dyspepsia, which is a side effect of common pain medications.
Certain herbs and supplements can help 'tummy aches'
As more parents choose home remedies for their children's gastrointestinal complaints, the question arises, which ones really work?
Simple breath test may replace endoscopy
A simple breath test for detecting H pylori infection is as effective and safe as endoscopy and is less uncomfortable and distressing for the patient, conclude researchers in this week’s BMJ.
H Pylori Eradication Reduces Risk Of Peptic Ulcers For Patients Taking Non-steroidal Anti-inflammatory Drugs
Screening and treatment for infection caused by the gastrointestinal bacterium Helicobacter pylori could substantially reduce the risk of ulcers for patients starting long-term non-steroidal anti-inflammatory drug (NSAID) treatment, conclude authors of a study in this week's issue of THE LANCET. A meta-analysis also published in this week's issue confirms both H pylori and NSAIDs as independent risk factors for peptic-ulcer disease. Whether H pylori increases the risk of ulcers in patients taking NSAIDs is controversial. Francis Chan and colleagues from Prince of Wales Hospital, Hong Kong, hypothesised that eradication of H pylori would reduce the risk of ulcers for patients starting long-t
More Dyspepsia Current Events and Dyspepsia News Articles
 | Dyspepsia (Fast Facts) by Kenneth L. Koch Wake Forest Univ., Winston-Salem, NC. Quick reference for non-specialists. Covers a wide range of interventions and the aids to differential diagnosis. Describes the various causes of dyspepsia and guidance on management of each condition.... |
| Dyspepsia and its kindred diseases by W. W Hall | |
 | Dyspepsia (Key Diseases Series) (Key Diseases Series) by David A. Johnson Dyspepsia provides the latest essential information organized in an easy-to-use format. Topics include epidemiology, etiology, natural history, motility problems, quality-of-life issues, and alternative therapies. The complexities of gastroesophageal reflux disease and Helicobacter pylori infection are explored. Clinical Vignettes demonstrate how experts approach frequently encountered dilemmas... |
 | Contemporary Diagnosis and Management of Dyspepsia and GERD by Peter J. Kahrilas, Colin W. Howden |
| Lectures On Dietics And Dyspepsia | |
| Audio Digest: Internal Medicine: Diabetic Renal Failure/Liver Disease/Dyspepsia (Vol. 48, Issue 8, April 21, 2001) by MD Frank C. Brosius, MD Laurel R. Fisher, James M. Scheiman Diabetes and renal failure; how to treat, when to refer. Hepatic steatosis: alcoholic and non-alcoholic liver disease. Evaluating and treating... | |
 | Dyspepsia: The Clinical Consequences St. James University Hospital, Leeds, UK. Reviews the understanding of what dyspepsia is, its impact on the community, its causes and diagnosis, and the methods of treatment. For gastroenterologists, surgeons, pathologists, and radiologists. DNLM:... |
| Ulcer and Non-Ulcer Dyspepsias (Practical Clinical Medicine) | |
| The Expert and Medical Progress: Experts' Influence on the Views of Peptic Ulcer and Dyspepsia and Its Treatment in Scandinavia During Five Decades (Comprehensive ... Summaries of Uppsala Dissertations, 877) by Herdis Molinder | |
| Artichoke leaf extract reduces mild dyspepsia in an open study.: An article from: Phytomedicine: International Journal of Phytotherapy & Phytopharmacology by G. Marakis, A.F. Walker, R.W. Middleton, J.C.L. Booth, J. Wright, D.J. Pike This digital document is an article from Phytomedicine: International Journal of Phytotherapy & Phytopharmacology, published by Urban & Fischer Verlag on December 1, 2002. The length of the article is 4320 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase.... |
| © 2009 BrightSurf.com |